Becton, Dickinson and (NYSE:BDX – Get Rating) announced its quarterly earnings data on Thursday. The medical instruments supplier reported $2.98 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.30, RTT News reports. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. The company had revenue of $4.59 billion during the quarter, compared to analyst estimates of $4.59 billion. During the same quarter last year, the firm posted $3.64 EPS. The firm's revenue for the quarter was down 2.8% on a year-over-year basis. Becton, Dickinson and updated its FY23 guidance to $12.07 to $12.32 EPS and its FY 2023 guidance to $12.07-$12.32 EPS.
Becton, Dickinson and Trading Down 1.1 %
BDX stock traded down $2.63 during trading on Friday, hitting $245.84. 2,117,947 shares of the company traded hands, compared to its average volume of 1,115,617. The firm has a market capitalization of $69.88 billion, a PE ratio of 46.38, a P/E/G ratio of 2.13 and a beta of 0.54. Becton, Dickinson and has a 1 year low of $215.90 and a 1 year high of $280.62. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.63 and a current ratio of 1.07. The company has a 50-day moving average of $251.67 and a 200-day moving average of $244.48.
Get
Becton Dickinson and alerts:
Becton, Dickinson and Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Stockholders of record on Friday, March 10th will be issued a $0.91 dividend. The ex-dividend date is Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and's payout ratio is 68.68%.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on BDX. Cowen reduced their price objective on shares of Becton, Dickinson and to $255.00 in a research note on Wednesday, November 16th. Bank of America upgraded Becton, Dickinson and from a "neutral" rating to a "buy" rating and lifted their price target for the company from $250.00 to $290.00 in a research report on Tuesday, January 3rd. Morgan Stanley lifted their target price on Becton, Dickinson and from $290.00 to $295.00 and gave the company an "overweight" rating in a report on Friday. The Goldman Sachs Group reduced their price objective on shares of Becton, Dickinson and from $319.00 to $272.00 and set a "buy" rating for the company in a research note on Wednesday, November 23rd. Finally, StockNews.com raised shares of Becton, Dickinson and from a "hold" rating to a "buy" rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and has an average rating of "Moderate Buy" and an average target price of $275.64.
Institutional Trading of Becton, Dickinson and
A number of institutional investors have recently modified their holdings of BDX. Kayne Anderson Rudnick Investment Management LLC lifted its position in Becton, Dickinson and by 18.2% during the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 94,253 shares of the medical instruments supplier's stock valued at $21,003,000 after buying an additional 14,501 shares during the period. Captrust Financial Advisors raised its position in Becton, Dickinson and by 7.3% in the 3rd quarter. Captrust Financial Advisors now owns 87,783 shares of the medical instruments supplier's stock worth $19,561,000 after buying an additional 5,986 shares during the last quarter. CreativeOne Wealth LLC raised its holdings in shares of Becton, Dickinson and by 6.5% during the third quarter. CreativeOne Wealth LLC now owns 2,565 shares of the medical instruments supplier's stock valued at $572,000 after purchasing an additional 157 shares during the last quarter. Jane Street Group LLC increased its position in Becton, Dickinson and by 136.7% during the third quarter. Jane Street Group LLC now owns 34,591 shares of the medical instruments supplier's stock valued at $7,708,000 after acquiring an additional 19,978 shares during the last quarter. Finally, Wealthsource Partners LLC purchased a new stake in Becton, Dickinson and during the third quarter valued at approximately $208,000. 87.08% of the stock is currently owned by hedge funds and other institutional investors.
Becton, Dickinson and Company Profile
(Get Rating)
Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.
Featured Articles
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.
